NCT04099134招募中不适用
PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma
University of Ulm1 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2018年10月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 5,000
- 试验地点
- 1
- 主要终点
- General assessment of applied therapy modalities in pancreatic cancer
研究概览
简要总结
PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection)
- •Age =>18 years
- •written informed consent
排除标准
- •papillary cancer
- •neuroendocrine pancreatic tumors
结局指标
主要结局
General assessment of applied therapy modalities in pancreatic cancer
时间窗: First diagnose to death or end of surveillance (5 years after curative resection)
Quality of life in pancreatic cancer patients
时间窗: First diagnose to death or end of surveillance (5 years after curative resection)
EORTC QLQ c30 and PAN 26
次要结局
- Assessment of tumor surveillance in pancreatic cancer patients(First diagnose to death or end of surveillance (5 years after curative resection))
- General epidemiologic assessment(First diagnose to death or end of surveillance (5 years after curative resection))
- Evaluation of predictive and prognostic markers(First diagnose to death or end of surveillance (5 years after curative resection))
研究者
Thomas Seufferlein
Head of department for internal medicine I
University of Ulm
研究点 (1)
Loading locations...
相似试验
招募中
不适用
REFLECT Scoliosis System Post Approval StudyIdiopathic ScoliosisNCT06298812Globus Medical Inc100
已完成
不适用
Remedy, Biodegradable Peripheral Stent RegistryPeripheral Arterial DiseaseNCT01420120be Medical100
Unknown
不适用
Revive AIS Patients ImmeDiatelyIschemic StrokeOcclusion, CerebrovascularNCT03007082Changhai Hospital100
招募中
不适用
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast CancerHER2-positive Breast CancerEarly-stage Breast CancerNCT06035016Peking Union Medical College Hospital300
已完成
不适用
Nellix Registry Study: EVAS-GlobalAbdominal Aortic AneurysmNCT02996396Endologix48